Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV16 SLP vaccination timed with carboplatin/paclitaxel chemotherapy in advanced cervical cancer
NL-OMON36470Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of hpv16 e6/e7 synthetic long peptide vaccine, carboplatin and paclitaxel in Cervical Cancer (CC) (2 cohorts), sponsored by Leiden University Medical Center. Primary endpoints: Time-related immune response during and after standard chemotherapy, Time- and treatment-related response to HPV16 SLP immunization and 1 more. Started Jan 2011; status: active, not recruiting.
02
Drugs
hpv16 e6/e7 synthetic long peptide vaccinecarboplatinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON36470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36470.